Business
Hikma Pharmaceuticals USA announces $1 Billion of new US investment to further expand its domestic manufacturing and development of essential generic medicines
In its ongoing mission to help meet America's growing need for high-quality US-made medicines, Hikma Pharmaceuticals USA today announces it will invest $1 billion by 2030 to further expand its US manufacturing and R&D capabilities. This new phase of investment -- America Leans on Hikma: Quality Medicines Manufactured in the USA – will further expand Hikma's well-established domestic capabilities to develop, produce and deliver a broad range of medicines needed by the US healthcare system to trea
About this update from Hikma Pharmaceuticals Plc
[{"type":"text","content":"Next phase builds on 34+ years of serving the needs of US patients and healthcare providers","length":91,"tagName":"p"},{"type":"text","content":"COLUMBUS, Ohio, June 28, 2025 /PRNewswire/ -- In its ongoing mission to help meet America's growing need for high-quality US-made medicines, Hikma Pharmaceuticals USA today announces it will invest $1 billion by 2030 to further expand its US manufacturing and R&D capabilities. This new phase of investment -- America Leans on Hikma: Quality Medicines Manufactured in the USA – will further expand Hikma's well-established domestic capabilities to develop, produce and deliver a broad range of medicines needed by the US healthcare system to treat patients nationwide.","length":580,"tagName":"p"},{"type":"image","alt":"(PRNewsfoto/Hikma Pharmaceuticals USA Inc.)","displaySize":"","headline":null,"caption":"(PRNewsfoto/Hikma Pharmaceuticals USA Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":108,"url":"https://media.zenfs.com/en/prnewswire.com/fcdee251665d184651b9926f5e9abe51"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/brP0E8SqJTDAbtPocMJv2A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTE5MDtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/fcdee251665d184651b9926f5e9abe51","width":400,"height":108}},"href":"https://mma.prnewswire.com/media/1165956/Hikma_Primary_Coral_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"Hikma has operated in the US since 1991 and has spent more than $4 billion over the past 15 years to build, enhance and expand its US-based R&D and manufacturing capabilities and now has annual domestic capacity to produce more than 12 billion finished doses of essential medicines. Over this period, Hikma has provided patients with access to a wide range of generic medicines at a lower cost than branded products. The company has an excellent record of US FDA quality inspections and has a successful record of working with FDA to solve critical drug shortages.","length":568,"tagName":"p"},{"type":"text","content":"Elected officials including US Rep. Mike Carey (OH-15) and US Rep. Buddy Carter (GA-01) joined Hikma at a special groundbreaking event held at the Company's state-of-the-art pharmaceutical manufacturing and R&D facility in Columbus, Ohio.","length":246,"tagName":"p"},{"type":"tex...